Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Local Ablative Therapy Might Extend TKI Benefit in NSCLC

December 24th 2012

Local ablative therapy plus continuation on the same tyrosine kinase inhibitor could be utilized as a treatment alternative in metastatic non-small cell lung cancer.

Novel Cancer Vaccine Fails To Significantly Improve Overall Survival in Lung Cancer

December 21st 2012

Results of a large phase III trial testing the efficacy of the investigational vaccine L-BLP25 in patients with advanced lung cancer found that the vaccine failed to show a statistically significant improvement in overall survival

Dr. Kris on Dacomitinib in EGFR-Positive Lung Cancer

December 12th 2012

Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center, discusses the administration of dacomitinib for patient with EGFR-positive lung cancer.

Dr. Gettinger on PD-1 Inhibitor BMS-936558 in NSCLC

December 11th 2012

Scott Gettinger, MD, from the Yale School of Medicine, discusses updated results from a phase I trial that examined the novel immunotherapy BMS-936558 in patients with NSCLC and other solid tumors.

EGFR Mutation Status Might Predict Sorafenib Benefit in NSCLC

November 30th 2012

Results of the phase III MISSION trial showed that third- or fourth-line treatment with sorafenib did not improve overall survival in patients with advanced non–small cell lung cancer.

Addition of Motesanib to Chemotherapy Offers No Benefit for Patients With Non-Small Cell Lung Cancer

November 27th 2012

Motesanib combined with carboplatin/paclitaxel does not significantly improve OS versus carboplatin/ paclitaxel alone in patients with advanced nonsquamous non–small cell lung cancer, according to the results of the phase III MONET1 study.

FDA Grants Orphan Drug Status to Amatuximab for Malignant Pleural Mesothelioma

November 12th 2012

Amatuximab has received orphan drug status from the FDA to treat patients with malignant pleural mesothelioma, the most common form of mesothelioma.

Dr. Kris Discusses Crizotinib in ALK-Positive Lung Cancer

November 2nd 2012

Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center, discusses the results of a phase III trial that studied the use of crizotinib in patients with advanced ALK-positive lung cancer.

No Survival Benefit Found When Adding Bevacizumab to Gemcitabine/Cisplatin in Malignant Mesothelioma

October 31st 2012

The addition of bevacizumab to gemcitabine/cisplatin does not significantly improve progression-free survival or overall survival in patients with previously untreated, unresectable malignant mesothelioma.

Dr. Gandara Describes Exciting Lung Cancer Research

October 24th 2012

David R. Gandara, MD, University of California, Davis Comprehensive Cancer Center, provides his opinion on some of the most exciting research currently taking place for patients with NSCLC.

Dacomitinib Bests Erlotinib in Advanced Non-Small Cell Lung Cancer

October 23rd 2012

Treatment with the investigational agent dacomitinib improved PFS when compared with erlotinib in patients with non–small cell lung cancer experiencing progression during chemotherapy.

7th New York Lung Cancer Symposium Provides Overview

October 22nd 2012

Targeted therapies, personalized medicine, and best management approaches will be the central topics of discussion at the 7th New York Lung Cancer Symposium.

Tackling Questions on Genetic Testing

October 19th 2012

The expansion of testing for genetic abnormalities in patients with advanced lung cancer is generating questions about which patients' tumors should be tested, how they should be tested, and whether they should be retested.

Dr. Langer on Targeted Agents for Locally Advanced NSCLC

October 19th 2012

Corey J. Langer, MD, from the Abramson Cancer Center, discusses the investigation of targeted therapies for patients with locally advanced non-small cell lung cancer.

Evolving Biologic Diversity Generates New Challenges

October 16th 2012

The heterogeneity of lung tumors generates challenges in terms of the costs and logistics of developing targeted therapies, given that relatively few patients may harbor a particular mutation.

FDA Approves Nab-Paclitaxel for Advanced Lung Cancer

October 12th 2012

The FDA has approved nab-paclitaxel plus carboplatin for patients with untreated locally advanced or metastatic NSCLC who are not candidates for surgery or radiation.

CT Screening Evolves Amid Questions and Controversy

October 10th 2012

Nearly 2 years after a landmark study supported CT for people at high risk of developing lung cancer, questions persist about the complexities of implementing an early detection program.

No Survival Benefit With Add-On Sorafenib in Advanced Lung Cancer

October 9th 2012

The addition of sorafenib to first-line gemcitabine/cisplatin does not appear to lengthen survival in patients with advanced, nonsquamous, non–small cell lung cancer.

From Survivor to Advocate: How One Patient Launched Two Foundations

October 5th 2012

As Bonnie Addario has gone from patient to survivor, she has learned much about what patients are looking for in terms of information and care.

Molecular Discoveries Pave Way for Rapid Advances in Lung Cancer

October 5th 2012

An interview with Giorgio V. Scagliotti, MD, who has played a prominent role in researching and developing therapies to attack molecular targets.